PANFIRE-3 Trial: Assessing Safety and Efficacy of Irreversible Electroporation (IRE) + Nivolumab + CpG for Metastatic Pancreatic Cancer
Irreversible Electroporation and Nivolumab Combined With Intratumoral Administration of a Toll-like Receptor Ligand as a Means of in Vivo Vaccination for Oligometastatic Pancreatic Ductal Adenocarcinoma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Florentine EF Timmer, MSc
- Phone Number: +3120 444 4571
- Email: f.timmer1@amsterdamumc.nl
Study Contact Backup
- Name: Bart Geboers, MD
- Phone Number: +3120 444 4571
- Email: b.geboers@amsterdamumc.nl
Study Locations
-
-
North-Holland
-
Amsterdam, North-Holland, Netherlands, 1081HV
- Recruiting
- Amsterdam University Medical Centre (location VUmc)
-
Contact:
- Florentine EF Timmer, MSc
- Phone Number: +3120 444 4571
- Email: f.timmer1@amsterdamumc.nl
-
Contact:
- Bart Geboers, MD
- Phone Number: +3120 444 4571
- Email: b.geboers@amsterdamumc.nl
-
Principal Investigator:
- Martijn R Meijerink, MD, PhD
-
Sub-Investigator:
- Florentine EF Timmer, MSc
-
Sub-Investigator:
- Bart Geboers, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Radiological and histopathologically proven stage IV pancreatic cancer (according to the AJCC staging system for pancreatic cancer);
- Primary oligometastatic disease, defined as at least 1 hepatic metastasis but occurrence of other metastases is not necessarily restricted to the liver, maximum of metastases is to be determined on a case by case basis by the multidisciplinary tumor board.
- Primary tumor is in situ.
- A minimum of 4 cycles of FOLFIRINOX chemotherapy is required but with the explicit aim to strive for completion of 8 cycles of FOLFIRINOX before study inclusion, with at least stable disease on CTscan.
- Age ≥ 18 years.
- World Health Organisation scale (WHO) performance status 0 - 2;
- Adequate bile drainage in case of biliary obstruction.
Exclusion Criteria:
- Trans-mucosal tumor invasion into surrounding duodenum or stomach;
- Active epilepsy (last convulsion < 5 years);
History of cardiac disease:
- Congestive heart failure > NYHA Class 2
- Active coronary artery disease (defined as myocardial infarction within 6 months prior to screening);
- Ventricular cardiac arrhythmias requiring anti-arrhythmic therapy or pacemaker (beta blockers for antihypertensive regimen are permitted; atrial fibrillation is not contra-indicated);
- Known hypersensitivity to any oligodeoxynucleotides.
- Compromised liver function defined as warning signs of portal hypertension, INR > 1,5 without use of anticoagulants, bilirubin > x 1.5 Upper limit of normal range (ULN) ASAT >3.0 x ULN, ALAT >3.0 x ULN.
- Compromised kidney function defined as eGFR <30 ml/min (using the Cockcroft Gault formula);
- Active autoimmune disease requiring disease-modifying therapy at the time of screening: i.e. > 10 mg prednisolone per day or equivalent to this regimen.
- Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen;
- Uncontrolled infections (> grade 2 NCI-CTC version 3.0); requiring antibiotics
- Pregnant or breast-feeding subjects; Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment;
- Immunotherapy prior to the procedure for the treatment of cancer;
- Previous surgical therapy for pancreatic cancer;
- Second primary malignancy with median 5 year OS < 90%, this excludes adequately treated cancers like: non-melanoma skin cancer, in situ carcinoma of the cervix uteri, superficial bladder cancer or other malignancies treated previously without signs of recurrence.
- Allergy to contrast agent.
- Allergy to PET tracers 18F-FDG and 18F-BMS-986192 Zr-89-Nivolumab
- Any implanted stimulation device;
- Portal vein or VMS stenosis > 70% (relative contra-indication)
- Any condition that is unstable or that could jeopardize the safety of the subject and their compliance in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Arm A: Nivolumab
4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will start with the Nivolumab scheme.
The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg.
This treatment will continue until disease progression.
|
Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells.
Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
|
|
Experimental: Arm B: IRE + Nivolumab
4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), the patient will first receive (an incomplete) IRE of the primary pancreatic tumor. 2 weeks thereafter, they will start the Nivolumab scheme.
The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg.
This treatment will continue until disease progression.
|
Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells.
Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
|
|
Experimental: Arm C: CpG + IRE + Nivolumab
4 weeks after pre-treatment with FOLFIRINOX (4-8 cycles), a toll-like receptor ligand (CpG) will be administered into the primary pancreatic tumor.
A week later, the patient will receive (an incomplete) IRE of the primary tumor. 2 weeks thereafter, they will start the Nivolumab scheme.
The first month, a biweekly dose of 240 mg will be administered, followed by a monthly dose of 480 mg.
This treatment will continue until disease progression.
|
Nivolumab is an immune checkpoint inhibitor targeting the PD-1 receptor on T-cells.
Binding of the PD-1 monoclonal antibody onto the PD-1 receptor blocks the brake signal on the T-cells, allowing them to attack the cancer cells.
Irreversible electroporation (IRE) is a local ablative technique that utilizes electrical pulses to destroy tumor tissue
Toll-Like Receptor 9 (CpG) is an oligodeoxynucleotide that stimulates dendritic cells to release IFN type I, activating natural killer and infiltrating T cells.
This creates a more pro-immunogenic tumor environment.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Safety of the combination treatment IRE + immunotherapy based on adverse events
Time Frame: From randomization until 1 year later
|
Determined by the treatment related (serious) adverse events
|
From randomization until 1 year later
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: From date of randomization until death, assessed up to 5 years
|
Overall survival in terms of months
|
From date of randomization until death, assessed up to 5 years
|
|
Progression-Free Survival
Time Frame: From date of randomization until unequivocal disease progression, assessed up to 5 years
|
Progression-free survival in terms of months
|
From date of randomization until unequivocal disease progression, assessed up to 5 years
|
|
Immunomodulation (local)
Time Frame: Biopsies taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
|
The local immune response will be assessed using flow cytometry and immunohistochemistry of 2 biopsies (1x primary, 1x metastasis).
Markers include those of T-cells, dendritic cells and others.
|
Biopsies taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
|
|
Immunomodulation (systemic)
Time Frame: Blood taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
|
The systemic immune response will be assessed using flow cytometry of peripheral blood.
Markers include those of T-cells, dendritic cells, MDSCs, NK cells.
|
Blood taken at T=0 (prior to treatment), T=2 weeks and T=6 weeks
|
|
Tumor Response on Imaging
Time Frame: PET scans at T= 0 (prior to treatment), T= 6 weeks and T=3months. CT scans will be made at T= 0 (prior to treatment), T= 6 weeks, T=3months, followed by a scan every subsequent 3 months (T=6m,9m,12m etc) until unequivocal disease progression.
|
Tumor response will be assessed using PET-CT scans: tracer uptake of FDG and PD-L1.
CT scans will be employed to determine tumor response based on the RECIST criteria.
|
PET scans at T= 0 (prior to treatment), T= 6 weeks and T=3months. CT scans will be made at T= 0 (prior to treatment), T= 6 weeks, T=3months, followed by a scan every subsequent 3 months (T=6m,9m,12m etc) until unequivocal disease progression.
|
|
Quality of Life throughout treatment based on overall health
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following EORTC questionnaire: EQ-5D-L5.
Question types include: scale 1-5
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on specific health questions
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following EORTC questionnaire: QLQ-C30 Question types include: scale 1-5, scale 1-7
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on Chemotherapy-Induced Peripheral Neuropathy
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following EORTC questionnaire: QLQ-CIPN20 Question types include: scale 1-4
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment specifically in patients with pancreatic cancer
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following EORTC questionnaire: QLQ-PAN26 Question types include: scale 1-4
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on the patient's happiness and emotional functioning
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following questionnaire: QLQ-HAPINES Question types include: scale 1-10
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on anxiety and depression
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following questionnaire: QLQ-HADS Question types include: scale 1-4
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on a patient's psychological state regarding their disease
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following questionnaire: QLQ-WOPS Question types include: scale 1-4, scale 1-10, yes/no, open
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Quality of Life throughout treatment based on (decreased) pancreatic functionality
Time Frame: Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Based on the following questionnaire: EPI Question types include: 5 optional answers, scale, 1-4, scale 1-5, yes/no, open
|
Quality of Life will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
|
Pain based on the Visual Analog Score (VAS)
Time Frame: Pain will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
The pain questionnaire is based on the VAS and includes scale type questions (1 - 10) with higher scores referring to more pain.
|
Pain will be assessed every 3 months (T=0 (baseline), T=3months, etc) up to 1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Martijn R Meijerink, MD, PhD, Amsterdam UMC, location VUmc
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Nivolumab
Other Study ID Numbers
Other Study ID Numbers
- 2020.231 - NL73415.029.20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.